NASDAQ Gainers: Rediff.com India Limited (ADR) (NASDAQ:REDF), Keurig Green Mountain Inc (NASDAQ:GMCR), Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)



Rediff.com India Limited (ADR) (NASDAQ:REDF) released its 4Q and full-year financial performance that showed somehow wanting results especially in the U.S. However, investors appeared to pay little attention to the U.S. business problems but instead looked forward to better results in the near future, just as the management promised. Rediff.com India Limited (ADR) (NASDAQ:REDF) stock performance was 23.01% in last session and finished the day at $2.94. Traded volume was 7.06million shares in the last session and the average volume of the stock remained 185.56K shares. The beta of the stock remained 4.27. Rediff.com India Limited (ADR) (NASDAQ:REDF) insider ownership is 13.74%.

Keurig Green Mountain Inc (NASDAQ:GMCR) flirted with a breakout from a cup-with-handle pattern. It was one of the top performers in the IBD 50, rising 8%. Keurig Green Mountain Inc (NASDAQ:GMCR) rose 8.39 percent to $122.07 Friday on volume of 5.67million shares. The intra-day range of the stock was $112.53 to $123.38. Keurig Green Mountain Inc (NASDAQ:GMCR) has a market capitalization of $19.87billion.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has seen shares climb more than 30 percent since the beginning of the week, a spike brought about by news that the European Medicines Agency has accepted Vanda’s flagship drug Hetlioz for evaluation. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)’s stock on June 06, 2014 reported a increase of 5.95% to the closing price of $13.71. Its fifty two weeks range is $5.70 -$19.25. The total market capitalization recorded $464.41million. The overall volume in the last trading session was 2.12million shares. In its share capital, VNDA has 33.87million outstanding shares.

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) on May 22 announced results demonstrating the potent anti-tumor and anti-cancer stem cell (CTC) effects of Ad-RTS-IL-12 in a glioma (brain cancer) model, and in other preclinical and clinical settings. Ad-RTS-IL-12 is a novel DNA-based therapeutic candidate for the controlled expression of IL-12, an important protein for stimulating an anti-cancer T cell immune response. The presentation, titled “Intratumoral Regulated Expression of IL-12 as a Gene Therapy Approach to Immunotherapy,” was presented in an oral session at the 17th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), held May 21-24 in Washington, DC. On Friday, shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) advanced 7.77% to close the day at $4.02. Company return on investment (ROI) is -116.80% and its monthly performance is recorded as 28.03%. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) quarterly revenue growth is -5.19%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone